Logo image of CALC

CALCIMEDICA INC (CALC) Stock Fundamental Analysis

NASDAQ:CALC - Nasdaq - US38942Q2021 - Common Stock - Currency: USD

2.35  -0.09 (-3.69%)

Fundamental Rating

2

CALC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. While CALC seems to be doing ok healthwise, there are quite some concerns on its profitability. CALC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CALC has reported negative net income.
CALC had a negative operating cash flow in the past year.
In the past 5 years CALC always reported negative net income.
CALC had a negative operating cash flow in each of the past 5 years.
CALC Yearly Net Income VS EBIT VS OCF VS FCFCALC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -83.81%, CALC is doing worse than 74.05% of the companies in the same industry.
CALC has a worse Return On Equity (-150.48%) than 66.49% of its industry peers.
Industry RankSector Rank
ROA -83.81%
ROE -150.48%
ROIC N/A
ROA(3y)-141.17%
ROA(5y)-113.19%
ROE(3y)-191.74%
ROE(5y)-153.42%
ROIC(3y)N/A
ROIC(5y)N/A
CALC Yearly ROA, ROE, ROICCALC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

CALC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALC Yearly Profit, Operating, Gross MarginsCALC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for CALC has been increased compared to 1 year ago.
The number of shares outstanding for CALC has been increased compared to 5 years ago.
CALC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CALC Yearly Shares OutstandingCALC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
CALC Yearly Total Debt VS Total AssetsCALC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

CALC has an Altman-Z score of -14.45. This is a bad value and indicates that CALC is not financially healthy and even has some risk of bankruptcy.
CALC's Altman-Z score of -14.45 is on the low side compared to the rest of the industry. CALC is outperformed by 81.08% of its industry peers.
CALC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.45
ROIC/WACCN/A
WACCN/A
CALC Yearly LT Debt VS Equity VS FCFCALC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 4.15 indicates that CALC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.15, CALC is in line with its industry, outperforming 60.00% of the companies in the same industry.
CALC has a Quick Ratio of 4.15. This indicates that CALC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.15, CALC is in the better half of the industry, outperforming 61.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.15
Quick Ratio 4.15
CALC Yearly Current Assets VS Current LiabilitesCALC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

CALC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.81%, which is quite impressive.
EPS 1Y (TTM)94.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.94% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.08%
EPS Next 2Y39.4%
EPS Next 3Y24.94%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CALC Yearly Revenue VS EstimatesCALC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026
CALC Yearly EPS VS EstimatesCALC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CALC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CALC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CALC Price Earnings VS Forward Price EarningsCALC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALC Per share dataCALC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CALC's earnings are expected to grow with 24.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.4%
EPS Next 3Y24.94%

More info and screens

0

5. Dividend

5.1 Amount

CALC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALCIMEDICA INC

NASDAQ:CALC (2/21/2025, 8:05:04 PM)

2.35

-0.09 (-3.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-26 2025-03-26/amc
Inst Owners52.43%
Inst Owner Change39.74%
Ins Owners11.99%
Ins Owner Change12.34%
Market Cap31.68M
Analysts84
Price Target16.32 (594.47%)
Short Float %0.65%
Short Ratio1.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.14%
Min EPS beat(2)1.3%
Max EPS beat(2)32.99%
EPS beat(4)4
Avg EPS beat(4)52.48%
Min EPS beat(4)1.3%
Max EPS beat(4)101.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.88%
EPS NQ rev (1m)-0.51%
EPS NQ rev (3m)-0.51%
EPS NY rev (1m)-3.21%
EPS NY rev (3m)0.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.51
P/tB 3.51
EV/EBITDA N/A
EPS(TTM)-1.08
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0
BVpS0.67
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.81%
ROE -150.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.17%
ROA(5y)-113.19%
ROE(3y)-191.74%
ROE(5y)-153.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.52%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.15
Quick Ratio 4.15
Altman-Z -14.45
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.63%
Cap/Depr(5y)155.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.02%
EPS Next Y95.08%
EPS Next 2Y39.4%
EPS Next 3Y24.94%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y45.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.05%
EBIT Next 3Y3.08%
EBIT Next 5YN/A
FCF growth 1Y26.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.06%
OCF growth 3YN/A
OCF growth 5YN/A